Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of alternative RTS,S/AS01E malaria vaccine dose and schedule regimens in children
2024-000563-20Phase 2
- Sponsor
- GSK
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RTS,S in malaria and hepatitis B (HBV), sponsored by GSK. Primary endpoint: Total IgG against NANP repeats region of circumsporozoite protein at 12 months after Dose 3.
02
Drugs
RTS,S
03
Conditions
malariahepatitis B (HBV)
Beyond the preview
Go deeper on 2024-000563-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000563-20.